Immunoglobulin M: Restrainer of Inflammation and Mediator of Immune Evasion by Plasmodium falciparum Malaria

Trends in Parasitology

Volumn 32, Issue 2, 2016, Pages 108-119

  Pleass, Richard J ^a   Moore, Shona C ^a,c   Stevenson, Liz ^b   Hviid, Lars ^b  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Fc receptors; IgM; Immune evasion; Immunoglobulin M; Plasmodium falciparum

Indexed keywords

CELL RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN M;

ANTIBODY RESPONSE; HOST; HUMAN; IMMUNE EVASION; IMMUNITY; IMMUNOGLOBULIN STRUCTURE; MALARIA FALCIPARUM; NONHUMAN; PARASITE SURVIVAL; REVIEW; ANIMAL; HOST PARASITE INTERACTION; IMMUNOLOGY; INFLAMMATION; PLASMODIUM FALCIPARUM;

ANIMALS; HOST-PARASITE INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNOGLOBULIN M; INFLAMMATION; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 84959109364     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2015.09.007     Document Type: Review

References (122)

1. Pleass R.J., Holder A.A. Antibody-based therapies for malaria. Nat. Rev. Microbiol. 2005, 3:893-899.
2. Hoffman S.L., et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 1987, 237:639-642.
3. Cowman A.F., Crabb B.S. Invasion of red blood cells by malaria parasites. Cell 2006, 124:755-766.
4. Chan J.A., et al. Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cell. Mol. Life Sci. 2014, 71:3633-3657.
5. Hviid L., Jensen A.T. PfEMP1 - a parasite protein family of key importance in Plasmodium falciparum malaria immunity and pathogenesis. Adv. Parasitol. 2015, 88:51-84.
6. Persson K.E., et al. Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity. J. Immunol. 2013, 191:785-794.
7. Bouharoun-Tayoun H., et al. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 1990, 172:1633-1641.
8. Boyle M.J., et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 2015, 42:580-590.
9. Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 2004, 5:981-986.
10. Heyman B., et al. Complement activation is required for IgM-mediated enhancement of the antibody response. J. Exp. Med. 1988, 167:1999-2004.
11. Ehrenstein M.R., Notley C.A. The importance of natural IgM: scavenger, protector and regulator. Nat. Rev. Immunol. 2010, 10:778-786.
12. Kaveri S.V., et al. Natural IgM in immune equilibrium and harnessing their therapeutic potential. J. Immunol. 2012, 188:939-945.
13. Klimovich V.B. IgM and its receptors: structural and functional aspects. Biochemistry 2011, 76:534-549.
14. Czajkowsky D.M., Shao Z. The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14960-14965.
15. Czajkowsky D.M., et al. IgM, FcμRs, and malarial immune evasion. J. Immunol. 2010, 184:4597-4603.
16. Ochsenbein A.F., et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999, 286:2156-2159.
17. Boes M., et al. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 1998, 188:2381-2386.
18. Vollmers H.P., Brandlein S. Natural IgM antibodies: the orphaned molecules in immune surveillance. Adv. Drug Deliv. Rev. 2006, 58:755-765.
19. Atkinson J.P., Frank M.M. Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J. Clin. Invest. 1974, 54:339-348.
20. Taborda C.P., Casadevall A. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 2002, 16:791-802.
21. Ogden C.A., et al. IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 2005, 38:259-264.
22. Peng Y., et al. The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol. Immunol. 2005, 42:781-787.
23. Quartier P., et al. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur. J. Immunol. 2005, 35:252-260.
24. Zhang M., Carroll M.C. Natural IgM-mediated innate autoimmunity: a new target for early intervention of ischemia-reperfusion injury. Expert Opin. Biol. Ther. 2007, 7:1575-1582.
25. Litvack M.L., et al. IgM promotes the clearance of small particles and apoptotic microparticles by macrophages. PLoS ONE 2011, 6:e17223.
26. Subramaniam K.S., et al. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J. Immunol. 2010, 184:5755-5767.
27. Connolly S.E., et al. Generation of a complement-independent bactericidal IgM against a relapsing fever Borrelia. J. Immunol. 2004, 172:1191-1197.
28. Racine R., Winslow G.M. IgM in microbial infections: taken for granted?. Immunol. Lett. 2009, 125:79-85.
29. Baumgarth N., et al. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J. Exp. Med. 2000, 192:271-280.
30. Salinas-Carmona M.C., Perez-Rivera I. Humoral immunity through immunoglobulin M protects mice from an experimental actinomycetoma infection by Nocardia brasiliensis. Infect. Immun. 2004, 72:5597-5604.
31. Konishi E., Nakao M. Naturally occurring immunoglobulin M antibodies: enhancement of phagocytic and microbicidal activities of human neutrophils against Toxoplasma gondii. Parasitology 1992, 104:427-432.
32. Baral T.N., et al. Control of Trypanosoma evansi infection is IgM mediated and does not require a type I inflammatory response. J. Infect. Dis. 2007, 195:1513-1520.
33. Rajan B., et al. Critical role for IgM in host protection in experimental filarial infection. J. Immunol. 2005, 175:1827-1833.
34. Alugupalli K.R., et al. The resolution of relapsing fever borreliosis requires IgM and is concurrent with expansion of B1b lymphocytes. J. Immunol. 2003, 170:3819-3827.
35. Choi Y.S., Baumgarth N. Dual role for B-1a cells in immunity to influenza virus infection. J. Exp. Med. 2008, 205:3053-3064.
36. Chen Y., et al. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J. Immunol. 2009, 182:6031-6043.
37. Shibuya A., et al. Fc α/μ receptor mediates endocytosis of IgM-coated microbes. Nat. Immunol. 2000, 1:441-446.
38. Kubagawa H., et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J. Exp. Med. 2009, 206:2779-2793.
39. Adachi T., et al. CD22 serves as a receptor for soluble IgM. Eur. J. Immunol. 2012, 42:241-247.
40. Czajkowsky D.M., et al. Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications. Sci. Rep. 2015, 5:9526.
41. Arnold J.N., et al. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J. Biol. Chem. 2005, 280:29080-29087.
42. Nauta A.J., et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur. J. Immunol. 2003, 33:2853-2863.
43. Chen Y., et al. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J. Immunol. 2009, 183:1346-1359.
44. Notley C.A., et al. Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J. Immunol. 2011, 186:4967-4972.
45. Grönwall C., et al. Protective roles of natural IgM antibodies. Front. Immunol. 2012, 3:66.
46. Vollmers H.P., et al. Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol. Rep. 1998, 5:35-40.
47. Warrington A.E., et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6820-6825.
48. Illert B., et al. Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer. Oncol. Rep. 2005, 13:765-770.
49. Banks W.A., et al. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp. Neurol. 2007, 206:248-256.
50. Beutner U., et al. Neoadjuvant therapy of gastric cancer with the human monoclonal IgM antibody SC-1: impact on the immune system. Oncol. Rep. 2008, 19:761-769.
51. Fleming S.D. Natural antibodies, autoantibodies and complement activation in tissue injury. Autoimmunity 2006, 39:379-386.
52. Stahl D., et al. Altered antibody repertoires of plasma IgM and IgG toward nonself antigens in patients with warm autoimmune hemolytic anemia. Hum. Immunol. 2001, 62:348-361.
53. Baudino L., et al. IgM and IgA anti-erythrocyte autoantibodies induce anemia in a mouse model through multivalency-dependent hemagglutination but not through complement activation. Blood 2007, 109:5355-5362.
54. Kaetzel C.S. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol. Rev. 2005, 206:83-99.
55. McEwan W.A., et al. Intracellular antibody-mediated immunity and the role of TRIM21. Bioessays 2011, 33:803-809.
56. Kubagawa H., et al. The long elusive IgM Fc receptor, FcμR. J. Clin. Immunol. 2014, 34(Suppl. 1):S35-S45.
57. Haegert D.G. Phagocytic peripheral blood monocytes from rabbits and humans express membrane receptors specific for IgM molecules: evidence that incubation with neuraminidase exposes cryptic IgM (Fc) receptors. Clin. Exp. Immunol. 1979, 35:484-490.
58. Tissot J.D., et al. IgM are associated to Spα (CD5 antigen-like). Electrophoresis 2002, 23:1203-1206.
59. Arai S., et al. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep. 2013, 3:1187-1198.
60. Sanjurjo L., et al. The human CD5L/AIM-CD36 axis: a novel autophagy inducer in macrophages that modulates inflammatory responses. Autophagy 2015, 11:487-502.
61. Kubagawa H., et al. Nomenclature of Toso, Fas apoptosis inhibitory molecule 3, and IgM FcR. J. Immunol. 2015, 194:4055-4057.
62. Briles D.E., et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J. Exp. Med. 1981, 153:694-705.
63. Harte P.G., et al. Specific monoclonal IgM is a potent adjuvant in murine malaria vaccination. Nature 1983, 302:256-258.
64. Couper K.N., et al. Parasite-specific IgM plays a significant role in the protective immune response to asexual erythrocytic stage Plasmodium chabaudi AS infection. Parasite Immunol. 2005, 27:171-180.
65. Bolad A., et al. Distinct interethnic differences in immunoglobulin G class/subclass and immunoglobulin M antibody responses to malaria antigens but not in immunoglobulin G responses to nonmalarial antigens in sympatric tribes living in West Africa. Scand. J. Immunol. 2005, 61:380-386.
66. Arama C., et al. Genetic resistance to malaria is associated with greater enhancement of immunoglobulin (Ig)M than IgG responses to a broad array of Plasmodium falciparum antigens. Open Forum Infect. Dis. 2015, 2:ofv118.
67. Yilmaz B., et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell 2014, 159:1277-1289.
68. Soares M.P., Yilmaz B. Microbiota control of malaria transmission. Trends Parasitol. 2016, 10.1016/j.pt.2015.11.004.
69. Gowda D.C., Davidson E.A. Protein glycosylation in the malaria parasite. Parasitol. Today 1999, 15:147-152.
70. Stanisic D.I., et al. Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. Infect. Immun. 2015, 83:646-660.
71. Kinyanjui S.M., et al. Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens. J. Infect. Dis. 2003, 187:667-674.
72. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol. Today 1993, 14:480-482.
73. Hurez V., et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 1997, 90:4004-4013.
74. Vassilev T., et al. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur. J. Immunol. 1999, 29:2436-2442.
75. Bieber A.J., et al. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 2002, 37:241-249.
76. Neilson A.R., et al. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J. Crit. Care 2005, 20:239-249.
77. Mekhaiel D.N., et al. Do regulatory antibodies offer an alternative mechanism to explain the hygiene hypothesis?. Trends Parasitol. 2011, 27:523-529.
78. Avila J.L., et al. Immunogenic Gal alpha 1→3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J. Immunol. 1989, 142:2828-2834.
79. El-Ekiaby M., et al. Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries. PLoS Negl. Trop. Dis. 2015, 9:e0003501.
80. Varambally S., et al. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int. Immunol. 2004, 16:517-524.
81. Vassilev T., et al. IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice. Clin. Exp. Immunol. 2006, 145:108-115.
82. Warrington A.E., Rodriguez M. Method of identifying natural antibodies for remyelination. J. Clin. Immunol. 2010, 30(Suppl. 1):S50-S55.
83. Czajkowsky D.M., et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol. Med. 2012, 4:1015-1028.
84. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu. Rev. Immunol. 2000, 18:709-737.
85. Sorman A., et al. How antibodies use complement to regulate antibody responses. Mol. Immunol. 2014, 61:79-88.
86. Shi J., et al. Antibody- and Fc-receptor-based therapeutics for malaria. Clin. Sci. 2006, 110:11-19.
87. Pleass R.J. Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol. 2009, 31:529-538.
88. Brown J., et al. Cellular mechanisms involved in recovery from acute malaria in Gambian children. Parasite Immunol. 1986, 8:551-564.
89. Boudin C., et al. Possible role of specific immunoglobulin M antibodies to Plasmodium falciparum antigens in immunoprotection of humans living in a hyperendemic area, Burkina Faso. J. Clin. Microbiol. 1993, 31:636-641.
90. Bate C.A.W., Kwiatkowski D. Inhibitory immunoglobulin M antibodies to tumor necrosis factor-inducing toxins in patients with malaria. Infect. Immun. 1994, 62:3086-3091.
91. Jeppesen A., et al. Multiple Plasmodium falciparum erythrocyte membrane protein 1 variants per genome can bind IgM via its Fc fragment Fcμ. Infect. Immun. 2015, 83:3972-3981.
92. Fried M., Duffy P.E. Adherence of Plasmodium falciparum to chondroitin sulphate A in the human placenta. Science 1996, 272:1502-1504.
93. Creasey A., et al. Nonspecific Immunoglobulin M binding and chondroitin sulfate A binding are linked phenotypes of Plasmodium falciparum isolates implicated in malaria during pregnancy. Infect. Immun. 2003, 71:4767-4771.
94. Salanti A., et al. Selective upregulation of a single distinctly structured var gene in CSA-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol. Microbiol. 2003, 49:179-191.
95. Salanti A., et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J. Exp. Med. 2004, 200:1197-1203.
96. Barfod L., et al. Evasion of immunity to Plasmodium falciparum malaria by IgM masking of protective IgG epitopes in infected erythrocyte surface-exposed PfEMP1. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12485-12490.
97. Tolia N.H., et al. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 2005, 122:183-193.
98. Maier A.G., et al. Polymorphisms in erythrocyte binding antigens 140 and 181 affect function and binding but not receptor specificity in Plasmodium falciparum. Infect. Immun. 2009, 77:1689-1699.
99. Singh S., et al. A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS ONE 2009, 4:e5410.
100. Batchelor J.D., et al. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat. Struct. Mol. Biol. 2011, 18:908-914.
101. Handunnetti S.M., et al. Uninfected erythrocytes form 'rosettes' around Plasmodium falciparum infected erythrocytes. Am. J. Trop. Med. Hyg. 1989, 40:115-118.
102. Udomsangpetch R., et al. Plasmodium falciparum-infected erythrocytes form spontaneous erythrocyte rosettes. J. Exp. Med. 1989, 169:1835-1840.
103. Clough B., et al. Plasmodium falciparum: the importance of IgM in the rosetting of parasite-infected erythrocytes. Exp. Parasitol. 1998, 89:129-132.
104. Scholander C., et al. Novel fibrillar structure confers adhesive property to malaria- infected erythrocytes. Nat. Med. 1996, 2:204-208.
105. Rowe J.A., et al. Nonimmune IgM, but not IgG binds to the surface of Plasmodium falciparum-infected erythrocytes and correlates with rosetting and severe malaria. Am. J. Trop. Med. Hyg. 2002, 66:692-699.
106. Carlson J., Wahlgren M. Plasmodium falciparum erythrocyte rosetting is mediated by promiscuous lectin-like interactions. J. Exp. Med. 1992, 176:1311-1317.
107. Kyriacou H.M., et al. In vitro inhibition of Plasmodium falciparum rosette formation by curdlan sulphate. Antimicrob. Agents Chemother. 2007, 51:1321-1326.
108. Vigan-Womas I., et al. Structural basis for the ABO blood-group dependence of Plasmodium falciparum rosetting. PLoS Pathog. 2012, 8:e1002781.
109. c-specific binding of IgM to Plasmodium falciparum erythrocyte membrane protein 1 mediating erythrocyte rosetting. Cell. Microbiol. 2015, 17:819-831.
110. 2-Macroglobulin can crosslink multiple Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) molecules and may facilitate adhesion of parasitized erythrocytes. PLoS Pathog. 2015, 11:e1005022.
111. Rask T.S., et al. Plasmodium falciparum erythrocyte membrane protein 1 diversity in seven genomes - divide and conquer. PLoS Comput. Biol. 2010, 6:e1000933.
112. Urban B.C., et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999, 400:73-77.
113. Urban B.C., et al. A role for CD36 in the regulation of dendritic cell function. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:8750-8755.
114. Adinolfi M., et al. X chromosome complement and serum levels of IgM in man and mouse. J. Immunogenet. 1978, 5:149-156.
115. McGue M., et al. Sex-linked determinants for IgM?. Hum. Hered. 1990, 40:231-234.
116. Kim H., et al. Functional roles for C5a and C5aR, but not C5L2, in the pathogenesis of human and experimental cerebral malaria. Infect. Immun. 2014, 82:371-379.
117. Weinmann O., et al. Up-regulation of C5a receptor expression and function on human monocyte derived dendritic cells by prostaglandin E2. Immunology 2003, 110:458-465.
118. Peng Q., et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. J. Immunol. 2009, 183:6058-6068.
119. Parsons M.S., et al. Harnessing CD36 to rein in inflammation. Endocr. Metab. Immune Disord. Drug Targets 2008, 8:184-191.
120. Semblat J.P., et al. Identification of Plasmodium falciparum var1CSA and var2CSA domains that bind IgM natural antibodies. Mol. Biochem. Parasitol. 2006, 146:192-197.
121. Ghumra A., et al. Identification of residues in the Cμ4 domain of polymeric IgM essential for interaction with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). J. Immunol. 2008, 181:1988-2000.
122. Semblat J.P., et al. Identification of the minimal binding region of a Plasmodium falciparum IgM binding PfEMP1 domain. Mol. Biochem. Parasitol. 2015, 201:76-82.